BR9811823A - Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias - Google Patents

Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias

Info

Publication number
BR9811823A
BR9811823A BR9811823-4A BR9811823A BR9811823A BR 9811823 A BR9811823 A BR 9811823A BR 9811823 A BR9811823 A BR 9811823A BR 9811823 A BR9811823 A BR 9811823A
Authority
BR
Brazil
Prior art keywords
allergic
compositions
allergic reactions
reactions
inflammatory diseases
Prior art date
Application number
BR9811823-4A
Other languages
English (en)
Inventor
Tahir Ahmed
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of BR9811823A publication Critical patent/BR9811823A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Patente de Invenção<B>"MéTODO E COMPOSIçõES PARA TRATAR REAçõES ALéRGICAS DE FASE TARDIA E DOENçAS INFLAMATóRIAS"<D>. Um método de tratar um paciente mamífero sofrendo de, ou propenso a uma condição caracterizada por reações alérgicas de fase tardia, hipersensibilidade da vias aéreas ou reações inflamatórias, por exemplo, a asma, a rinite alérgica, a dermatite alérgica, a conjuntivite alérgica, a doença inflamatória do intestino ou a artrite reumatóide, compreendendo a administração ao paciente de uma composição farmacêutica oral, parenteral, intrabrónquica, tópica, intranasal ou intra-ocular, contendo, em cada dose, cerca de 0,005 a cerca de 1,0mg, por quilograma de peso do corpo do paciente, de heparinas de peso molecular ultrabaixo (ULMWH) ou outros polissacarídeos sulfatados, tendo pesos moleculares médios de cerca de 1.000-3.000 dáltons. São também divulgadas composições farmacêuticas inalantes adequadas, e outras, para uso no novo método de tratamento.
BR9811823-4A 1997-08-04 1998-08-04 Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias BR9811823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/904,565 US5980865A (en) 1995-08-18 1997-08-04 Method for treating late phase allergic reactions and inflammatory diseases
PCT/US1998/016111 WO1999006025A1 (en) 1997-08-04 1998-08-04 Method and compositions for treating late phase allergic reactions and inflammatory diseases

Publications (1)

Publication Number Publication Date
BR9811823A true BR9811823A (pt) 2000-08-15

Family

ID=25419368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811823-4A BR9811823A (pt) 1997-08-04 1998-08-04 Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias

Country Status (26)

Country Link
US (2) US5980865A (pt)
EP (1) EP1003479B1 (pt)
JP (1) JP2001511439A (pt)
KR (1) KR100551773B1 (pt)
CN (1) CN1092049C (pt)
AR (1) AR005221A1 (pt)
AT (1) ATE323500T1 (pt)
AU (1) AU8684698A (pt)
BR (1) BR9811823A (pt)
CA (1) CA2298445C (pt)
DE (1) DE69834256T2 (pt)
DK (1) DK1003479T3 (pt)
ES (1) ES2260843T3 (pt)
HK (1) HK1030370A1 (pt)
HU (1) HUP0003013A3 (pt)
IL (1) IL134230A0 (pt)
NO (1) NO20000558L (pt)
NZ (1) NZ502498A (pt)
PL (1) PL191796B1 (pt)
PT (1) PT1003479E (pt)
RU (1) RU2209624C2 (pt)
SK (1) SK1172000A3 (pt)
TW (1) TW585771B (pt)
UA (1) UA75022C2 (pt)
WO (1) WO1999006025A1 (pt)
ZA (1) ZA986890B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9917092D0 (en) * 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
ES2315479T5 (es) 2002-02-18 2015-07-01 Ockham Biotech Limited Empleo de glicosaminoglicanos tales como p.ej. Heparina para el tratamiento de trastornos respiratorios tales como COPD
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
CN1627948A (zh) * 2002-04-24 2005-06-15 麦迪卡博公司 治疗炎症性肠病的组合物和试剂盒
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
EP1607095A1 (en) * 2003-03-25 2005-12-21 Sekisui Chemical Co., Ltd. Antipruritic composition for external use on skin
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
WO2006026998A1 (en) * 2004-09-10 2006-03-16 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
JP5167133B2 (ja) 2005-09-14 2013-03-21 マンカインド コーポレイション 結晶性微粒子表面に対する活性薬剤の親和性の増大に基づく薬物処方の方法
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN101095693B (zh) * 2006-06-29 2010-10-13 重庆华邦制药股份有限公司 治疗皮炎的复方药物
EP2164501B1 (en) * 2007-05-31 2016-04-20 Paradigm Biopharmaceuticals Limited Sulphated xylans for treatment or prophylaxis of respiratory diseases
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101672684B1 (ko) 2008-06-13 2016-11-03 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
BRPI1013154B1 (pt) 2009-06-12 2020-04-07 Mannkind Corp Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
WO2011068721A1 (en) * 2009-12-03 2011-06-09 Opko Health, Inc. Hypersulfated disaccharide formulations
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
MX2013004575A (es) * 2010-10-29 2013-05-17 Opko Health Inc Disacaridos hipersulfatados para tratar trastornos relacionados con la elastasa.
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
UY34069A (es) * 2011-05-12 2013-01-03 Aventis Pharma Sa Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CN104114152A (zh) 2011-12-07 2014-10-22 阿勒根公司 用盐敏性乳液体系对人泪液膜进行有效脂质递送
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送***和方法
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
EP3500583A1 (en) 2016-08-16 2019-06-26 OPKO Pharmaceuticals, LLC Pure heptasulfated disaccharides having improved oral bioavailability
CN110291073A (zh) 2016-12-13 2019-09-27 贝塔医疗私人有限公司 乙酰肝素酶抑制剂及其用途
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
US20220211746A1 (en) * 2021-01-07 2022-07-07 Bionovax Corp. Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
KR100235782B1 (ko) * 1991-05-02 1999-12-15 파울리나 벤-아미 병리학적 과정의 예방 또는 치료를 위한 성분물
CA2156735A1 (en) * 1993-02-22 1994-09-01 Ulrich-Christoph Von Arnim Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases
FR2704861B1 (fr) * 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9303612D0 (sv) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
CA2298445C (en) 2007-07-17
PL191796B1 (pl) 2006-07-31
RU2209624C2 (ru) 2003-08-10
NO20000558D0 (no) 2000-02-03
US5980865A (en) 1999-11-09
HUP0003013A3 (en) 2001-11-28
PT1003479E (pt) 2006-08-31
HK1030370A1 (en) 2001-05-04
DK1003479T3 (da) 2006-07-31
DE69834256T2 (de) 2007-02-01
EP1003479A1 (en) 2000-05-31
CN1092049C (zh) 2002-10-09
PL338551A1 (en) 2000-11-06
KR100551773B1 (ko) 2006-02-13
NZ502498A (en) 2002-05-31
JP2001511439A (ja) 2001-08-14
TW585771B (en) 2004-05-01
US6193957B1 (en) 2001-02-27
WO1999006025A1 (en) 1999-02-11
UA75022C2 (en) 2006-03-15
CA2298445A1 (en) 1999-02-11
KR20010022533A (ko) 2001-03-15
AU8684698A (en) 1999-02-22
ZA986890B (en) 1999-01-28
CN1269715A (zh) 2000-10-11
ATE323500T1 (de) 2006-05-15
NO20000558L (no) 2000-03-14
DE69834256D1 (de) 2006-05-24
EP1003479B1 (en) 2006-04-19
IL134230A0 (en) 2001-04-30
EP1003479A4 (en) 2001-01-17
SK1172000A3 (en) 2001-03-12
HUP0003013A2 (hu) 2001-01-29
AR005221A1 (es) 1999-04-28
ES2260843T3 (es) 2006-11-01

Similar Documents

Publication Publication Date Title
BR9811823A (pt) Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
WO2001036510A3 (en) Use of poly(diallylamine) polymers
BR9607066A (pt) Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos
IL133585A0 (en) Soluble prodrugs of paclitaxel
MXPA00009159A (es) Formulaciones de dextrano y metodo para el tratamiento de desordenes inflamatorios de articulaciones.
BR0108386C1 (pt) urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida
IL174991A0 (en) Steroidal sapogenins and their derivatives for treating alzheimer&#39;s disease
BR9809951A (pt) Método para tratamento da obesidade
WO2001010907A3 (en) Therapeutic polypeptides and methods for using same
JP2009143947A (ja) ビタミン、金属塩、およびインスリンまたは成長ホルモンを含有する治療用の組成物
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
EP0797999A3 (en) Formulations of obesity protein
HUE030224T2 (en) Low molecular weight biotechnological chondroitin 6-sulphate to prevent osteoarthritis
JP2004531460A (ja) 炎症性関節炎の抑制のためのヒアルロン酸誘導体の使用
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
JP2003089647A (ja) 関節性疾患治療剤
WO2004084912A1 (ja) 神経障害処置剤
Rubin et al. Oral polymeric N-acetyl-D-glucosamine and osteoarthritis
CA2516322A1 (en) Glycosaminoglycan-dnase combination therapy
ES2281265B1 (es) Composiciones para el tratamiento de la artrosis.
WO2005084610A2 (en) New therapeutic use for a group of sulphated polysaccharides
BR0015270A (pt) Método e composições para tratamento de doenças pulmonares

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 10-VIII DA LPI9.279/96